Combining new drugs to improve treatment for brain tumors
Novel DNA damage response inhibitor and alkylator combinations for GBM
This study is looking at new ways to boost the effectiveness of standard chemotherapy for glioblastoma by combining it with special drugs that help the body respond to DNA damage, and patients may have the chance to participate in trials to see how these combinations work.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10923879 on NIH RePORTER |
What this research studies
This research investigates the use of novel DNA damage response inhibitors in combination with traditional alkylating chemotherapy agents to enhance treatment outcomes for patients with glioblastoma (GBM). The approach focuses on understanding how different DNA damage caused by these treatments activates specific cellular responses, which can be manipulated to improve therapy effectiveness. By collaborating with pharmaceutical companies, the research aims to identify the best combinations of drugs that can penetrate the blood-brain barrier and work synergistically with existing treatments. Patients may be involved in trials to test these new combinations and monitor their effects on tumor response.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing or have undergone standard chemotherapy treatments.
Not a fit: Patients with other types of brain tumors or those who have not been diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with glioblastoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with similar approaches, indicating potential for significant advancements in glioblastoma treatment.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Bindra, Ranjit — Mayo Clinic Rochester
- Study coordinator: Bindra, Ranjit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.